{"id":7628,"date":"2016-11-18T12:21:50","date_gmt":"2016-11-18T11:21:50","guid":{"rendered":"https:\/\/www.worldpolicyconference.com\/?p=7628"},"modified":"2026-03-20T16:41:33","modified_gmt":"2026-03-20T15:41:33","slug":"arthur-stril","status":"publish","type":"post","link":"https:\/\/www.worldpolicyconference.com\/fr\/arthur-stril\/","title":{"rendered":"Arthur Stril"},"content":{"rendered":"<p><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Directeur financier de Cellectis, soci\u00e9t\u00e9 de biotechnologie cot\u00e9e au NASDAQ qui utilise sa plateforme d\u2019\u00e9dition de g\u00e9nome pour d\u00e9velopper des th\u00e9rapies innovantes pour le traitement de maladies graves, notamment en oncologie. \u00c0 ce titre, il supervise les finances, le business development et les relations investisseurs. Sa carri\u00e8re a d\u00e9but\u00e9 \u00e0 la Direction g\u00e9n\u00e9rale de la concurrence de la Commission europ\u00e9enne o\u00f9 il a supervis\u00e9 des fusions internationales dans le secteur pharmaceutique, notamment les \u00e9changes d&rsquo;actifs entre Novartis\/GSK et Sanofi\/Boehringer Ingelheim, ainsi que l\u2019acquisition d&rsquo;Hospira par Pfizer et celle d&rsquo;Actavis Generics par Teva. Par la suite, il a rejoint le minist\u00e8re de la Sant\u00e9 en tant que responsable du bureau charg\u00e9 du financement des \u00e9tablissements de sant\u00e9, o\u00f9 il dirigeait une \u00e9quipe en charge du budget hospitalier de 80 milliards d&rsquo;euros. Ancien \u00e9l\u00e8ve de l&rsquo;ENS Ulm et de l&rsquo;Universit\u00e9 de Cambridge, Arthur Stril est titulaire d\u2019un dipl\u00f4me en Th\u00e9rapeutiques Immunologiques de l&rsquo;universit\u00e9 Paris-Descartes. Il est \u00e9galement ing\u00e9nieur du Corps des Mines et membre du comit\u00e9 consultatif de Life Science Cares, une organisation \u00e0 but non lucratif am\u00e9ricaine.<\/span><\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Directeur financier de Cellectis, soci\u00e9t\u00e9 de biotechnologie cot\u00e9e au NASDAQ qui utilise sa plateforme d\u2019\u00e9dition de g\u00e9nome pour d\u00e9velopper des th\u00e9rapies innovantes pour le traitement de maladies graves, notamment en<\/p>\n","protected":false},"author":3,"featured_media":17837,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[21,22,25,157],"class_list":["post-7628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-invited-guests","tag-21","tag-22","tag-25","tag-157"],"_links":{"self":[{"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/posts\/7628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/comments?post=7628"}],"version-history":[{"count":0,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/posts\/7628\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/media\/17837"}],"wp:attachment":[{"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/media?parent=7628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/categories?post=7628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.worldpolicyconference.com\/fr\/wp-json\/wp\/v2\/tags?post=7628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}